Pharma Reaserch Prod Co Ltd (214450) — Cash Flow-to-Debt Ratio
Pharma Reaserch Prod Co Ltd (214450) has a Cash Flow-to-Debt Ratio of 0.19x as of December 2025, meaning its operating cash flow of ₩61.53 Billion could theoretically repay 0% of its total liabilities (₩320.01 Billion) in one year. See 214450 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Pharma Reaserch Prod Co Ltd Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Pharma Reaserch Prod Co Ltd across 11 annual periods. Also explore 214450 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Pharma Reaserch Prod Co Ltd (2015–2025)
Year-by-year debt coverage analysis for Pharma Reaserch Prod Co Ltd. For market capitalisation and broader financial context, see Pharma Reaserch Prod Co Ltd (214450) total market value.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.57x | ₩183.16 Billion | ₩320.01 Billion | ▲ +17.1% |
| 2024 | 0.49x | ₩139.88 Billion | ₩286.26 Billion | ▼ -45.0% |
| 2023 | 0.89x | ₩64.95 Billion | ₩73.09 Billion | ▲ +101.3% |
| 2022 | 0.44x | ₩59.40 Billion | ₩134.55 Billion | ▼ -17.4% |
| 2021 | 0.53x | ₩65.30 Billion | ₩122.20 Billion | ▲ +22.7% |
| 2020 | 0.44x | ₩32.39 Billion | ₩74.41 Billion | ▲ +37.4% |
| 2019 | 0.32x | ₩19.27 Billion | ₩60.85 Billion | ▲ +268.6% |
| 2018 | 0.09x | ₩5.20 Billion | ₩60.56 Billion | ▼ -89.8% |
| 2017 | 0.84x | ₩8.56 Billion | ₩10.18 Billion | ▼ -20.8% |
| 2016 | 1.06x | ₩8.16 Billion | ₩7.69 Billion | ▼ -16.8% |
| 2015 | 1.28x | ₩16.02 Billion | ₩12.56 Billion | — |